Content - SAKK 06/17

Immunotherapy in combination with standard chemotherapy in patients with operable cancer of the urinary tract

In this trial, we are examining the efficacy and tolerability of the antibody durvalumab (a form of immunotherapy) in patients with surgically removable cancer of the urinary tract (bladder or urethra). Participants will be given a combination of the standard treatment (chemotherapy preceding and following surgery) plus the trial medication durvalumab. The aim of the trial is to improve the prognosis of the patients affected. Preoperative treatment will last three months, and will be followed by nine months of post-operative treatment.

Durvalumab has not yet been approved in Switzerland. It is a protein that activates the body’s immune system. Durvalumab has already been tested in a variety of cancer types, including cancers of the urinary tract, and has demonstrated highly promising efficacy as a stand-alone treatment. As yet, it has not been tested prior to surgery for urinary tract cancer and its clinical benefits cannot therefore be assessed.

This trial will be conducted at various centres in Switzerland and Germany. A total of 61 patients will be treated in the study. The first results of the trial are expected once all patients have been enrolled and followed up for an average of two years. This is expected to be in 2023.


Study Chair:

PD Dr. med. Richard Cathomas, Cantonal Hospital Graubünden, +41 81 256 66 95

Locations for this trial:

Kantonsspital Graubünden
Loëstrasse 170
7000 Chur
Klinik Hirslanden im Park
Seestrasse 259
0 8002 Zürich
Kantonsspital St. Gallen
Rorschacher Strasse 95
0 9007 St. Gallen
Universitätsspital Basel
Petersgraben 4
0 4031 Basel
Hôpitaux Universitaires de Genève HUG
Rue Gabrielle-Perret-Gentil 4
0 1205 Genève
Kantonsspital Baden
Im Ergel 1
4600 Baden
Kantonsspital Aarau
Tellstrasse 25
0 5001 Aarau
Freiburgstrasse 8
3010 Bern
Centre Hospitalier Universitaire Vaudois CHUV
Rue du Bugnon 46
0 Lausanne